- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04962854
Changes of Bone Mineral Density in Total Hip Arthroplasty
Changes of Bone Mineral Density in Total Hip Arthroplasty - A Prospective Comparison of Isoelastic and Metal-backed Cup Designs
Study Overview
Status
Conditions
Detailed Description
The study was performed as a prospective, single center study at the Department of Orthopedics, Sacred Heart of Jesus Hospital Vienna, Austria.
Inclusion criteria were as follows: any patient aged from 18 years onwards undergoing primary cementless THA for degenerative joint disease, including osteoarthritis, post-traumatic arthritis, congenital hip dysplasia and avascular necrosis. Excluded were all patients with malignant diseases and pregnant women, additionally, patients were excluded if severe complications such as fracture or revision surgery occurred during the study period.
Patients were enrolled from January 2016 to May 2017, a total of 117 patients were included. All patients underwent uncemented THA, patients either received a monoblock cup (RM Pressfit vitamys®; Mathys Ltd. Bettlach, Switzerland), or a titanium shell (ANA.NOVA® Implantec, Mödling, Austria). DEXA measurements according to the DeLee and Charnley Zones were performed postoperatively, 3, 6, 12 and 24 months after primary hip arthroplasty. Bone mineral density (BMD) was measured by using the bone densiometer (Lunar, Prodigy, GE Medical Sytsems). A special legholder was used to fix the leg to ensure the same rotation and avoid measurement errors. DEXA measurements were performed and analyzed by two trained authors. Statistical analysis focused on differences in BMD between monoblock cup and modular cup after 3, 6, 12 and 24 months as well as changes in BMD in relation to cup inclination. In order to gain valid results, the nonparametric Wilcoxon rank-sum test was used. We used t-Test to evaluate differences to the baseline. A probability value of p ≤0.05 was considered as statistically significant. Data was analyzed using Microsoft Excel® and SPSS® (version 26.0, SPSS Inc., Chicago, IL, USA) representing standard statistical software. We hypothesized that the more elastic monoblock cup performs better than the more rigid modular cup with regard to changes in BMD.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- any patient aged from 18 years onwards undergoing primary cementless THA for degenerative joint disease, including osteoarthritis, post-traumatic arthritis, congenital hip dysplasia and avascular necrosis.
Exclusion Criteria:
- patients with malignant diseases and pregnant women, additionally, patients were excluded if severe complications such as fracture or revision surgery occurred during the study period.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Monoblock Cup
53 patients received a monoblock cup (RM Pressfit vitamys®)
|
|
Modular Cup
64 patients received a modular cup (ANA.NOVA® Implantec)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dexa meassurments
Time Frame: 24 Months
|
Changes in BMD according to DeLee and Charnley Zones
|
24 Months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- DEXA THA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Mineral Density
-
State University of New York - Upstate Medical...Completed
-
Duramed ResearchCompletedBone Mineral DensityUnited States
-
St. Jude Children's Research HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedBone Mineral Density | Bone StrengthUnited States
-
University of California, San FranciscoMayo ClinicCompletedBone Mineral DensityUnited States
-
University of AarhusCompletedBone Mineral Density | Osseointegrated Implants
-
Children's Hospital Medical Center, CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Tel-Aviv Sourasky Medical CenterUnknownBone Mineral Density | Vegan DietIsrael
-
Universidade Norte do ParanáCompletedBone Mineral Density Quantitative Trait Locus 3Brazil
-
Ain Shams UniversityCompletedBone Mineral Density Quantitative Trait Locus 3Egypt
-
Guiyang Medical UniversityCompletedBone Mineral Density Quantitative Trait Locus 7